GLPwatch
Papers (10588)
Page 163 of 177, ranked by citation count.
- [High dosage GLP-1 analogs are now available].
- Semaglutide alleviates ovarian ferroptosis in polycystic ovary syndrome and is associated with reduced GPX4 promoter hypermethylation.
- Orforglipron and the emergence of oral GLP-1 therapy for obesity: efficacy, safety, and clinical positioning.
- [SURPASS CVOT : cardiovascular benefits with tirzepatide versus dulaglutide in type 2 diabetes].
- Retatrutide in type 2 diabetes mellitus and obesity: an overview.
- Characterization of Interchanging Incretin Analogs in Clinical Practice: A Descriptive Report.
- Examination of quality of life in patients using exenatide with different dimensions.
- Reply.
- Comment on the Meta-analysis of Liraglutide for Weight Regain: Methodological Considerations.
- Gewichtsabnahme ist mit Semaglutid signifikant grösser als mit Liraglutid.
- The Gastrointestinal Safety of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.
- Effect of baseline characteristics on the efficacy of dulaglutide added to basal insulin in Chinese patients with type 2 diabetes: A subgroup analysis of AWARD-CHN3.
- Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 <i>post hoc</i> analysis.
- Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study.
- Assessment of noninferiority of oral vs subcutaneous semaglutide: a systematic review and meta-analysis.
- Liraglutid verzögert Diabetesentstehung.
- Fibrillar and Micellar Aggregation of Semaglutide and Formation of a Chiral-Imprinted Glass.
- [Promising molecules for treatment of hyperglycemia in patients with type 2 diabetes].
- Response to the Letter by Kalra S. et al.
- Liraglutide in diabetes mellitus: More facts and findings.
- Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study.
- Effect of tirzepatide on prediabetics and blood pressure with implications for future research.
- Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety.
- Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
- Semaglutide in Metabolic Medicine: <i>A Review on Clinical Applications and Emerging Therapeutics</i>.
- [Treatment of type 2 diabetes mellitus--which role do GLP-1 receptor agonists play?].
- [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
- Development of an electrochemiluminescence immunoassay for quantitative determination of semaglutide in human serum.
- Comparative effectiveness of tirzepatide and DPP-4 inhibitors in type 2 diabetes with heart failure.
- Incretin-based cardiovascular protection beyond diabetes: evidence, mechanisms, and therapeutic frontiers from GLP-1 receptor agonists to multi-agonist therapy.
- [New hypoglycemic agents in type 2 diabetes].
- Glucagon-like peptide 1 agonists for type 2 diabetes, weight loss, or both?
- Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis.
- Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy.
- Blamed but not at fault: Anti-obesity medication adverse effects misidentified as perioperative complications - a comprehensive review and medicolegal warning for anesthesiologists.
- Weight Management With Semaglutide and Tirzepatide in U.S. Adults: Projected Impact on Obesity Prevalence and Heart Failure Risk.
- A Rare Case of Tirzepatide-Associated Immune Thrombocytopenia.
- The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model.
- Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects.
- Association of tirzepatide with erectile dysfunction in people with type 2 diabetes.
- American Society for Metabolic and Bariatric Surgery statement on the treatment options for patients with non-response and weight recurrence after metabolic and bariatric surgery.
- Glucagon-like Peptide-1 Receptor Agonists in Liver Transplant Recipients: A Retrospective Cohort Study.
- Renoprotective effects of dulaglutide, a GLP-1 agonist, involving regulation of epithelial-mesenchymal transition in patients with type 2 diabetes and diabetic kidney disease.
- [Changes in weight and diabetes compensation (HbA(1c)) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic - BIBY-I study (observations lasting 3 to 12 months)].
- In brief: Removal of suicidality warning from GLP-1 Agonists for weight management.
- In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER.
- Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
- [Weight reducing and glucose reducing effects of liraglutide treatment for patients with type 2 diabetes].
- Acute liver injury associated with tirzepatide: An unexpected adverse event warranting clinical attention.
- Liraglutide ameliorates diabetic lung injury and muscle damage via modulation of TLR4/NF-κB and Atrogin-1/AMPK signaling pathways.
- Tirzepatide Synergizes with Leptin on Weight Loss and Restoring Metabolic Homeostasis in Diet-induced Obesity Model.
- Roux-en-Y Gastric Bypass Compared to Glucagon-Like Peptide-1 Receptor Agonists is Associated with Lower Out-of-Pocket Costs in Insured Patients with Type 2 Diabetes and Obesity: A Matched Analysis Over Two Years.
- Exploring the off-label use of liraglutide in the treatment of obesity: a review.
- Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis.
- [Cloning, expressing of exendin-4 analogue and bioactivity analysis in vivo].
- [The perspectives in obesity and type 2 diabetes therapy: the present and future of incretin therapy].
- Oral GLP-1 receptor agonists for the treatment of obesity: ATTAINing metabolic benefits to find the OASIS.
- Challenges in the management of obesity.
- Reestimation of Medicare Spending for Semaglutide After Most Favored Nation and Medicare Drug Price Negotiation Announcements.
- Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study.